Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary - Thomson StreetEvents

Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary

Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary - Thomson StreetEvents
Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary
Published May 27, 2019
16 pages (8606 words) — Published May 27, 2019
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of NOVN.S conference call or presentation 27-May-19 2:30pm GMT

  
Brief Excerpt:

...A. Overview: Received two approvals on 05/24/19, Zolgensma and Piqray. 1. 2. Zolgensma: a. First-ever gene therapy approved for spinal muscular atrophy. b. One of the first systemic gene therapies approved in whole new era of gene therapies where Co. aspires to be long-term leader. c. Indicated for treatment of pediatric patients less than two years of age with SMA. d. As part of approval, received rare pediatric priority review voucher. In situation where Co. will be able to ship products within next two weeks. i. e. Approved for broad range of pediatric patients with SMA. i. Any patients diagnosed with SMA under two years of age regardless of SMN2 copy number. ii. Includes symptomatic or pre-symptomatic patients. iii. It's for broad range of SMA patients under two years of age where Co. believes patients can fundamentally benefit from groundbreaking therapy....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Novartis AG
Ticker
NOVN.S
Time
2:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Novartis AG Q2 2020 Earnings Call Transcript – 2020-07-21 – US$ 54.00 – Edited Transcript of NOVN.S earnings conference call or presentation 21-Jul-20 12:00pm GMT

Novartis AG to Discuss the Oncology Pipeline Update Call Transcript – 2020-06-15 – US$ 54.00 – Edited Transcript of NOVN.S conference call or presentation 15-Jun-20 1:00pm GMT

Novartis AG Q2 2019 Earnings Call Summary – 2019-07-18 – US$ 54.00 – Edited Brief of NOVN.S earnings conference call or presentation 18-Jul-19 12:00pm GMT

Novartis AG Q2 2019 Earnings Call Transcript – 2019-07-18 – US$ 54.00 – Edited Transcript of NOVN.S earnings conference call or presentation 18-Jul-19 12:00pm GMT

Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Transcript – 2019-05-27 – US$ 54.00 – Edited Transcript of NOVN.S conference call or presentation 27-May-19 2:30pm GMT

Novartis AG Mayzent FDA Approval Investor Call Transcript – 2019-03-27 – US$ 54.00 – Edited Transcript of NOVN.S conference call or presentation 27-Mar-19 11:45am GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary" May 27, 2019. Alacra Store. May 12, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Novartis-AG-to-Discuss-the-Zolgensma-and-Piqray-US-FDA-Approvals-Call-B12564330>
  
APA:
Thomson StreetEvents. (2019). Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary May 27, 2019. New York, NY: Alacra Store. Retrieved May 12, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Novartis-AG-to-Discuss-the-Zolgensma-and-Piqray-US-FDA-Approvals-Call-B12564330>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.